Mannkind (MNKD) Asset Writedowns and Impairment (2017 - 2026)
Mannkind's (MNKD) quarterly Asset Writedowns and Impairment came in at $1.1 million in Q1 2026, up 130.69% year-on-year from $466000.0 in Q1 2025, and down 48.81% on a QoQ basis from $2.1 million in Q4 2025.
Mannkind (MNKD) Asset Writedowns and Impairment (2017 - 2026) Analysis & Trends
Mannkind (MNKD) has 9 years of Asset Writedowns and Impairment data on file, last reported at $1.1 million in Q1 2026.
- On a quarterly basis, Asset Writedowns and Impairment rose 130.69% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $11.1 million, a 234.39% increase from a year earlier, with the FY2025 full-year figure at $10.4 million, up 169.78% from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at $1.1 million, down from $2.1 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for MNKD reached as high as $4.6 million in Q2 2025 and fell as low as $300000.0 in Q3 2023.
- Historically, Asset Writedowns and Impairment has averaged $1.4 million across 5 years, with a median of $950000.0 in 2022.
- Across the five-year window, Asset Writedowns and Impairment tumbled 66.67% in 2023 and jumped 1000.0% in 2025, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at $802000.0 in 2022, then grew by 8.98% to $874000.0 in 2023, then soared by 122.65% to $1.9 million in 2024, then advanced by 7.91% to $2.1 million in 2025, then plunged by 48.81% to $1.1 million in 2026.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $1.1 million in Q1 2026, $2.1 million in Q4 2025, and $3.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Mannkind | 1.23 Bn | 1.10 Bn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.08 Mn |
| Mar 31, 2026 | 1.08 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Jun 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 4.60 Mn |
| Mar 31, 2025 | 466,000.00 |
| Mar 31, 2025 | 466,000.00 |
| Dec 31, 2024 | 1.95 Mn |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 600,000.00 |
| Jun 30, 2024 | 600,000.00 |
| Mar 31, 2024 | 1.03 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 874,000.00 |
| Dec 31, 2023 | 874,000.00 |